Karen Marie Walker - 15 Dec 2025 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Reporting relationship: Chief Technology Officer
Issuer ticker: KYTX
Reported as of: 15 Dec 2025
Net transaction value: -$176,865
SEC form: 4
Accepted by SEC: 17 Dec 2025, 20:30:03 UTC
Prior SEC filing: 15 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Samantha Eldredge, as Attorney-in-Fact

Key filing fact

Karen Marie Walker filed Form 4 for Kyverna Therapeutics, Inc. (KYTX) on 17 Dec 2025.

Key facts

This page summarizes Karen Marie Walker's Form 4 filing for Kyverna Therapeutics, Inc. (KYTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Dec 2025, 20:30.

Change

Previous filing in this sequence was filed on 15 Apr 2025.
Current net transaction value: -$176,865.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002008556 Primary reporting owner

Walker Karen Marie

Relationship: Chief Technology Officer
Address: C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 550, EMERYVILLE
Signature: /s/ Samantha Eldredge, as Attorney-in-Fact
Signature date: 17 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYTX transaction

Common Stock

Options Exercise

Transaction value: $115,910
Shares: +23,998
Change %: +106%
Price: $4.83
Shares after: 46,634
Date: 15 Dec 2025
Ownership: Direct
Footnotes: F1

KYTX transaction

Common Stock

Sale

Transaction value: $292,776
Shares: -23,998
Change %: -51%
Price: $12.20
Shares after: 22,636
Date: 15 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYTX transaction Derivative

Stock option (right to buy)

Options Exercise

Transaction value: $0
Shares: -23,998
Change %: -22%
Price: $0.000000
Shares after: 85,865
Date: 15 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,998
Exercise price: $4.83
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions.

Footnote F2

25% of the original number of shares subject to the option vested on January 1, 2025, and 1/48th of the original number of shares subject to the option vests in monthly installments thereafter, subject to the Reporting Person's continuous service.